oa COVID-19 and patients on renal replacement therapy: Perspective from the State of Qatar

References

1. Valeri AM, Robbins-Juarez SY, Stevens JS, Ahn W, Rao MK, Radhakrishnan J, et al.. Presentation and Outcomes of Patients with ESKD and COVID-19. J Am Soc Nephrol. 2020Jul; 31:(7):1409-1415. doi: 10.1681/ASN.2020040470
   [Google Scholar]
2. Kular D, Chis Ster I, Sarnowski A, Lioudaki E, Braide-Azikiwe DCB, Ford ML, et al.. The Characteristics, Dynamics, and the Risk of Death in COVID-19 Positive Dialysis Patients in London, UK. Kidney360. 2020Sep10; 1:(11):1226-1243. doi: 10.34067/KID.0004502020
   [Google Scholar]
3. Alberici F, Delbarba E, Manenti C, Econimo L, Valerio F, Pola A, et al.. A report from the Brescia Renal COVID Task Force on the clinical characteristics and short-term outcome of hemodialysis patients with SARS-CoV-2 infection. Kidney Int. 2020Jul; 98:(1):20-26. doi: 10.1016/j.kint.2020.04.030
   [Google Scholar]
4. Jager KJ, Kramer A, Chesnaye NC, Couchoud C, Sánchez-álvarez JE, Garneata L, et al.. Results from the ERA-EDTA Registry indicate a high mortality due to COVID-19 in dialysis patients and kidney transplant recipients across Europe. Kidney Int. 2020Dec; 98:(6):1540-1548. doi: 10.1016/j.kint.2020.09.006
   [Google Scholar]
5. Ghonimi TAL, Alkadi MM, Abuhelaiqa EA, Othman MM, Elgaali MA, Ibrahim RAM, et al.. Mortality and associated risk factors of COVID-19 infection in dialysis patients in Qatar: A nationwide cohort study. PLoS One. 2021Jul22; 16:(7):e0254246. doi: 10.1371/journal.pone.0254246
   [Google Scholar]
6. Alkadi MM, Al-Malki HA, Asim M, Fituri OM, Hamdi AF, Elidrisi RI, et al.. Kidney Transplant Recipients Infected With Coronavirus Disease 2019: Retrospective Qatar Experience. Transplant Proc. 2021Oct; 53:(8):2438-2446. doi: 10.1016/j.transproceed.2021.06.001
   [Google Scholar]
7. Asim M, Alkadi M, Hamad A, Othman M, Abuhelaiqa E, Fituri O, et al.. Restructuring nephrology services to combat COVID-19 pandemic: Report from a Middle Eastern country. World J Nephrol. 2020Nov29; 9:(2):9-17. https://doi.org/10.5527/wjn.v9.i2.9
   [Google Scholar]
8. Mohapatra RK, Tiwari R, Sarangi AK, Islam MR, Chakraborty C, Dhama K. Omicron (B.1.1.529) variant of SARS-CoV-2: Concerns, challenges, and recent updates. J Med Virol. 2022Jun1[cited 2022 Oct 10]; 94:(6):2336. doi: 10.1002/jmv. 27633
   [Google Scholar]
9. Hamad AI, Asim M, Othman MA, Abuhelaiqa EA, Shurrab A, Elmadhoun IT, et al.. National response to the COVID-19 Omicron variant crisis in the ambulatory hemodialysis service in the State of Qatar. Qatar Med J. 2022Aug23; 2022:(3):38. doi: 10.5339/qmj.2022.38
   [Google Scholar]
10. Hamad A, Elgaali M, Ghonimi T, Elshirbeny M, Ali M, Ibrahim R, et al.. From past to present: Exploring COVID-19 in Qatar’s hemodialysis population across Omicron dominant and pre-Omicron periods. PLoS One. 2023Sep14; 18:(9):e0291266. doi: 10.1371/journal.pone.0291266
    [Google Scholar]
11. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al.. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020Dec31; 383:(27):2603-2615. doi: 10.1056/NEJMoa2034577
    [Google Scholar]
12. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al.. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2021Feb4; 384:(5):403-416. doi: 10.1056/NEJMoa2035389
    [Google Scholar]
13. Oliver MJ, Thomas D, Balamchi S, Ip J, Naylor K, Dixon SN, et al.. Vaccine Effectiveness Against SARS-CoV-2 Infection and Severe Outcomes in the Maintenance Dialysis Population in Ontario, Canada. J Am Soc Nephrol. 2022Apr; 33:(4):839-849. doi: 10.1681/ASN.2021091262
    [Google Scholar]
14. Sibbel S, McKeon K, Luo J, Wendt K, Walker AG, Kelley T, et al.. Real-World Effectiveness and Immunogenicity of BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines in Patients on Hemodialysis. J Am Soc Nephrol. 2022Jan; 33:(1):49-57. doi: 10.1681/ASN.2021060778
    [Google Scholar]
15. Albayat S, Almaslamani M, Alromaihi H, Khogali H, Mundodan J, Joury J, et al.. Key Lessons from COVID-19: A Narrative Review Describing Qatar’s Multifactorial Approach in Executing a Vaccination Campaign. Vaccines (Basel). 2023May6; 11:(5):953. doi: 10.3390/vaccines11050953
    [Google Scholar]
16. Alkadi MM, Hamad A, Ghazouani H, Elshirbeny M, Ali MY, Ghonimi T, et al.. Effectiveness of Messenger RNA Vaccines against SARS-CoV-2 Infection in Hemodialysis Patients: A Case-Control Study. Vac- cines (Basel). 2022Dec26; 11:(1):49. doi: 10.3390/vaccines11010049
    [Google Scholar]
17. Chemaitelly H, AlMukdad S, Joy JP, Ayoub HH, Yassine HM, Benslimane FM, et al.. SARS-CoV-2 vaccine effectiveness in immunosuppressed kidney transplant recipients. doi: 10.1101/2021.08.07.21261578
    [Google Scholar]